Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced the promotion of Andrew Ratz to chief technical operations officer, elevating him to the executive management team.

Ratz will oversee the company's global technical development, manufacturing, and supply chain functions as Neurocrine expands beyond small molecules into biologics and device-based therapies, according to a company statement.

The executive joined Neurocrine in January 2025 as senior vice president of drug development, delivery and device. He previously spent nearly 30 years at Eli Lilly and Company, where he held broad responsibility across drug and device development and delivery of solutions from preclinical development through global manufacturing.

During his tenure at Lilly, Ratz contributed to the development and registration of more than 25 medicines across multiple therapeutic areas and drug modalities, supporting both biologic and small molecule portfolios.

"Since joining Neurocrine, Andy has brought visionary leadership and strategic focus to our R&D organization," said Kyle Gano, chief executive officer of Neurocrine Biosciences. "His skills and experience will help guide the company as we advance the next generation of treatments for patients with significant unmet needs."

Ratz holds a Bachelor of Science degree in Chemistry from Indiana University and earned his Ph.D. in Chemistry from Harvard University.

The San Diego-based biopharmaceutical company develops treatments for neurological, psychiatric, endocrine and immunological disorders. Its portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids.